Efficacy of subcutaneous (CT-P13) and IV Infliximab in adult
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
In Europe, a subcutaneous (SC) formulation of the infliximab biosimilar CT-P13 has been approved for the treatment of adult rheumatoid arthritis patients (RA). In comparison to intravenous (IV) infliximab formulations, it can provide better efficacy.

A network meta-regression was conducted using individual patient data from two randomised trials in patients with RA, which compared CT-P13 SC with CT-P13 IV, and CT-P13 IV with reference infliximab IV.

Outcomes included changes from baseline in 28-joint Disease Activity Score based on C-reactive protein (DAS28-CRP), Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI), and rates of remission, low disease activity or clinically meaningful improvement in functional disability per Health Assessment Questionnaire–Disability Index (HAQ-DI).

--The two studies enrolled 949 patients with RA; pooled data for 840 and 751 patients were evaluable at weeks 30 and 54, respectively.

--For the CT-P13 SC versus pooled IV treatment arm comparison, differences in changes from baseline in DAS28-CRP (-0.578), CDAI (-3.502) and SDAI (-4.031) scores at 30 weeks were statistically significant in favour of CT-P13 SC.

--From weeks 30 to 54, the magnitude of the differences increased and remained statistically significant in favour of CT-P13 SC.

--Similar results were observed for the comparison of CT-P13 SC with CT-P13 IV and with reference infliximab IV. Statistically significant differences at week 30 favoured CT-P13 SC over the pooled IV treatment arms for the proportions of patients achieving EULAR-CRP good response, American College of Rheumatology (ACR) 50 and ACR70 responses, DAS28-CRP-defined remission, low disease activity and clinically meaningful HAQ-DI improvement.

In comparison to CT-P13 IV and reference infliximab IV, CT-P13 SC was correlated with greater improvements in DAS28-CRP, CDAI, and SDAI ratings, as well as higher rates of clinical response, low disease activity, and clinically relevant improvement in functional impairment.

Source: https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-021-02487-x